Enliven Therapeutics, Inc. (ELVN)
NASDAQ: ELVN · IEX Real-Time Price · USD
17.37
-0.25 (-1.42%)
Apr 23, 2024, 4:00 PM EDT - Market closed

Company Description

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer.

The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.

The company is headquartered in Boulder, Colorado.

Enliven Therapeutics, Inc.
Enliven Therapeutics logo
Country United States
Founded 2016
IPO Date Mar 12, 2020
Industry Biotechnology
Sector Healthcare
Employees 46
CEO Samuel S. Kintz M.B.A.

Contact Details

Address:
6200 Lookout Road
Boulder, Colorado 80301
United States
Phone 720-647-8519
Website enliventherapeutics.com

Stock Details

Ticker Symbol ELVN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $16.00
CIK Code 0001672619
ISIN Number US29337E1029
Employer ID 81-1523849
SIC Code 2834

Key Executives

Name Position
Samuel S. Kintz M.B.A. Co-Founder, Chief Executive Officer, Secretary and Director
Benjamin Hohl Chief Financial Officer and Head of Corporate Development
Dr. Helen Louise Collins M.D. Chief Medical Officer
Dr. Joseph P. Lyssikatos Ph.D. Co-Founder, Chief Scientific Officer and Directors
Anish Patel Pharm.D. Co-Founder and Chief Operating Officer
Dr. Galya D. Blachman Esq., Ph.D. Chief Legal Officer and Head of Business Development

Latest SEC Filings

Date Type Title
Apr 18, 2024 S-3 Registration statement under Securities Act of 1933
Apr 15, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Apr 15, 2024 PRE 14A Other preliminary proxy statements
Apr 11, 2024 144 Filing
Apr 11, 2024 144 Filing
Apr 11, 2024 144 Filing
Apr 11, 2024 144 Filing
Apr 11, 2024 144 Filing
Apr 11, 2024 144 Filing
Apr 11, 2024 144 Filing